Dashboard/RYTM/RM-718/event

ReadoutTopline Readout

RM-718 Phase 2 Obesity Topline

RYTM·RM-718·Obesity·

Phase 2

·NCT06251271

current best date

'26

QTR5 months

Takeaway

Phase 2 efficacy readout for Rhythm’s next-gen weekly MC4R agonist in adult general (not BBS-specific) obesity. Watch: % weight loss vs. placebo, dose-response, hyperpigmentation rate vs. setmelanotide.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~14%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAweekly MC4R agonist (next-gen)

RM-718 is Rhythm Pharmaceuticals' next-generation MC4R agonist designed for once-weekly dosing, in contrast to the daily injections required by IMCIVREE (setmelanotide). Like setmelanotide, RM-718 activates the melanocortin-4 receptor in the hypothalamus to reduce hunger and improve energy expenditure, but its extended half-life supports a more convenient weekly administration schedule. Rhythm is evaluating RM-718 in adults with broader general obesity — beyond the rare genetic syndromes covered by IMCIVREE — to assess potential for a wider commercial opportunity.

Indication

Obesity / GLP-1

Obesity

MeSH · D009765

No primer in glossary yet.

Trial

recruiting

NCT06251271 ↗

STAR Phase 2 of RM-718 in Adult Obesity

Sector base rates · reference data

historical record · not prediction

of 4 historical Phase 2 readouts in Obesity / GLP-1: 3 positive, 1 mixed, 0 negative.

Positive

3/ 4

75%

Mixed

1/ 4

25%

Negative

0/ 4

positive rate 75% · primary endpoint hit rate 100%

Reference data · comparable readouts

How Ph2 readouts in Obesity / GLP-1 have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

3/4

75% in record

Primary endpoint hit

100%

across 4 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

AMG 133 (maritide)

AMGN · Obesity

Ph2 · Nov 2024mixed−20% body weight — high GI AE rate8-K

VK2735

VKTX · Obesity

Ph2 · Feb 2024positive−14.7% body weight at 13 wkPR

retatrutide

LLY · Obesity

Ph2 · Jun 2023positive−24.2% body weight at 48 wkconference

orforglipron

LLY · Obesity

Ph2 · Jun 2023positive−14.7% body weight at 36 wkconference

cagrisema

NVO · Obesity

Ph3 · Dec 2024mixed−22.7% — below internal 25% bar8-K

semaglutide 50mg oral

NVO · Obesity

Ph3 · May 2023positive−15.1% body weight at 68 wkPR

tirzepatide (SURMOUNT-1)

LLY · Obesity

Ph3 · Apr 2022positive−22.5% body weight at 72 wk vs −2.4% pboPR

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

2 peers in Obesity / GLP-1 · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Phase	Next catalyst
dapiglutide	VKTX	peptide	dual GLP-1 / GIP receptor agonist		CONFERENCE · May 26
IMCIVREEsetmelanotide	RYTM	peptide	MC4R agonist		PDUFA · Aug 26

Prior RYTM reactions to Readout events

1 historical event · base rate, not prediction

Median 1W move

+28.5%

Median 1M move

+43.3%

Positive outcomes

1/ 1

100%

Negative outcomes

0/ 1

Date	Headline	Outcome	1W	1M	6M
Jul 2024	RM-718 — Phase 2b Topline Met Primary Endpoint	positive	+28.5%	+43.3%	+26.0%

Historical RYTM stock reaction to past Readout catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 100%.

Disclosure trail

1 observation · sorted by confidence

Mar 18, 2026·1mo agopinned · highest confidence
HIGH conf8-K
top claim
Q4'26
QTR
“We expect topline Phase 2 results for RM-718 in adult obesity in the fourth quarter of 2026.”
conf 88%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.